1,001 Shares in Chemed Corporation $CHE Bought by Bayforest Capital Ltd

Key Points

• Bayforest Capital Ltd invested approximately $616,000 in Chemed Corporation, acquiring 1,001 shares in the 1st quarter, amidst a trend of institutional investors increasing their stakes in the company.
• Chemed also increased its quarterly dividend from $0.50 to $0.60, representing a 0.5% dividend yield.
• Despite a missed earnings target in their latest quarterly report, analysts maintain a consensus "Buy" rating for Chemed with an average price target of $592.25.

Bayforest Capital Ltd acquired a new stake in shares of Chemed Corporation (NYSE:CHE - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,001 shares of the company's stock, valued at approximately $616,000.

A number of other large investors also recently bought and sold shares of CHE. Alpine Bank Wealth Management purchased a new position in Chemed during the first quarter worth approximately $29,000. HM Payson & Co. acquired a new stake in shares of Chemed in the first quarter worth $30,000. SVB Wealth LLC acquired a new stake in shares of Chemed in the first quarter worth $30,000. Whipplewood Advisors LLC grew its holdings in Chemed by 54.5% during the 1st quarter. Whipplewood Advisors LLC now owns 51 shares of the company's stock valued at $31,000 after purchasing an additional 18 shares in the last quarter. Finally, WPG Advisers LLC acquired a new stake in Chemed during the 1st quarter valued at $32,000. Hedge funds and other institutional investors own 95.85% of the company's stock.

Chemed Stock Down 0.8%

Shares of Chemed stock traded down $3.70 during trading on Monday, hitting $442.70. The stock had a trading volume of 54,088 shares, compared to its average volume of 141,657. The company has a market capitalization of $6.45 billion, a PE ratio of 22.78, a P/E/G ratio of 2.60 and a beta of 0.46. The stock has a 50 day simple moving average of $451.83 and a 200 day simple moving average of $530.54. Chemed Corporation has a 1 year low of $408.42 and a 1 year high of $623.60.

Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $4.27 EPS for the quarter, missing the consensus estimate of $6.02 by ($1.75). The company had revenue of $618.80 million for the quarter, compared to analyst estimates of $650.60 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%.The business's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.47 earnings per share. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities analysts expect that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 11th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. This is a boost from Chemed's previous quarterly dividend of $0.50. The ex-dividend date was Monday, August 11th. Chemed's dividend payout ratio is presently 12.34%.

Insider Buying and Selling at Chemed

In other Chemed news, EVP Nicholas Michael Westfall sold 10,012 shares of Chemed stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $421.91, for a total value of $4,224,162.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George J. Walsh III bought 200 shares of Chemed stock in a transaction on Monday, August 4th. The stock was acquired at an average price of $417.10 per share, with a total value of $83,420.00. Following the completion of the purchase, the director directly owned 3,523 shares of the company's stock, valued at approximately $1,469,443.30. The trade was a 6.02% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 3.29% of the company's stock.

Analyst Upgrades and Downgrades

CHE has been the subject of a number of recent analyst reports. Oppenheimer lowered their price target on shares of Chemed from $650.00 to $580.00 and set an "outperform" rating for the company in a report on Thursday, July 31st. Royal Bank Of Canada decreased their price objective on shares of Chemed from $640.00 to $589.00 and set an "outperform" rating for the company in a report on Thursday, July 31st. Wall Street Zen downgraded shares of Chemed from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Bank of America reduced their price target on shares of Chemed from $610.00 to $595.00 and set a "buy" rating on the stock in a research report on Wednesday, September 10th. Finally, Jefferies Financial Group upgraded shares of Chemed from a "hold" rating to a "buy" rating and raised their price target for the stock from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $578.50.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.